# US 2025/0207202 A1 · Methods and compositions for identifying hox gene signatures to assign specific and effective therapies in acute myeloid leukemia and other cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0207202 A1
- Document ID: US20250207202A1
- Status: Published application
- Kind: A1
- Application number: 18/876,856
- Filed: 2023-07-03
- Published: 2025-06-26
- Earliest claimed: 2022-07-01
- Assignees: Ohio State Innovation Foundation
- Applicants: Ohio State Innovation Foundation
- Inventors: Christopher OAKES; James BLACHLY; John BYRD
- Web page: https://patentgrep.com/patent/US20250207202A1

## CPC

- A61P 35/00: Antineoplastic agents
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6809: Methods for determination or identification of nucleic acids involving differential detection
- C12Q 1/6827: for detection of mutation or polymorphism
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/154: Methylation markers
- G16H 50/30: for calculating health indices; for individual health risk assessment
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

The present disclosure provides kits and/or methods of detecting and identifying epigenetic patterns associated with acute myeloid leukemia and other cancers. The present disclosure also relates to treating, preventing, ameliorating, or reducing acute myeloid leukemia and other cancers.

## Claims

### Claim 1

A method of treating a subject with cancer, the method comprising:
a) obtaining a tissue sample from the subject;
b) extracting a nucleic acid from the tissue sample;
c) analyzing an epigenetic pattern of the nucleic acid;
d) comparing the epigenetic pattern from the subject to a control panel;
e) categorizing the subject into an epitype selected from epitype 1, epitype 2, epitype 3, epitype 4, epitype 5, epitype 6, epitype 7, epitype 8, epitype 9, epitype 10, epitype 11, epitype 12, or epitype 13 based on the epigenetic pattern; and
f) administering a treatment to the subject according to the at least one epitype.

### Claim 2 (depends on 1)

The method of claim 1, wherein the epigenetic pattern comprises a methylation of a deoxyribonucleic acid (DNA) sequence.

### Claim 3 (depends on 2)

The method of claim 2, wherein the methylation comprises a hypermethylation or a hypomethylation.

### Claim 4 (depends on 1)

The method of claim 1, wherein the methylation occurs at a cytosine-phosphate-guanosine (CpG) island of the nucleic acid.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cancer comprises an acute myeloid leukemia (AML).

### Claim 6 (depends on 1)

The method of claim 1, wherein the treatment method comprises regular monitoring by a physician.

### Claim 7 (depends on 1)

The method of claim 1, wherein the treatment comprises a drug.

### Claim 8 (depends on 7)

The method of claim 7, wherein the drug is a Menin inhibitor.

### Claim 9 (depends on 1)

The method of claim 1, wherein the subject retains a methylation pattern associated with a tumor genetic marker yet lacks the tumor genetic marker.

### Claim 10 (depends on 9)

The method of claim 9, wherein the genetic marker comprises FLT3-ITD, KMT2A, or NPM1.

### Claim 11 (depends on 1)

The method of claim 1, wherein the thirteen epitypes are further divided into 4 superclusters (SC) selected from a transcription factor (TF)-SC, a MLL-SC, a NPM1-SC, or a stem-cell like (SL)-SC.

### Claim 12

The method of 11, wherein the TF-SC comprises epitype 1, epitype 2, epitype 3, or epitype 4.

### Claim 13 (depends on 11)

The method of claim 11, wherein the TF-SC comprises a disruption to one or more transcription factors (TFs).

### Claim 14 (depends on 11)

The method of claim 11, wherein the MLL-SC comprises epitype 5 or epitype 6.

### Claim 15 (depends on 11)

The method of claim 11, wherein the MLL-SC comprises a rearrangement of a KMT2A/MLL gene.

### Claim 16 (depends on 11)

The method of claim 11, wherein the NPM1-SC comprises epitype 7, epitype 8, epitype 9, or epitype 10.

### Claim 17 (depends on 11)

The method of claim 11, wherein the NPM1-SC comprises at least one NPM1 mutation.

### Claim 18 (depends on 11)

The method of claim 11, wherein the SL-SC comprises epitype 11, epitype 12, or epitype 13.

### Claim 19 (depends on 11)

The method of claim 11, wherein the SL-SC displays DNA methylation patterns similar to DNA methylation patterns in hematopoietic stem cells.

### Claim 20 (depends on 3)

The method of claim 3, wherein the hypomethylation occurs at a signal transducer and activator of transcription (STAT) gene.

### Claim at position 21

21-32. (canceled)
